Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Internal Medicine Neurology Oncology Pediatrics Respiratory Medicine Surgery
Congress Coverage
2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting

Keynote Webinar | Spotlight on Diet and Diabetes

Watch on-demand

An expert-led symposium exploring the prevention and management of type 2 diabetes through dietary interventions. 
ADVANCED SEARCH
Log in
Top
Journal of Cancer Research and Clinical Oncology

Open Access 20-11-2023 | Research

Niosomal formulation of mefenamic acid for enhanced cancer targeting; preparation, characterization and biodistribution study using radiolabeling technique

Authors: Mona A. Shewaiter, Adli A. Selim, Hassan M. Rashed, Yasser M. Moustafa, Shadeed Gad

Published in: Journal of Cancer Research and Clinical Oncology

Login to get access

Abstract

Background

This work aimed to prepare niosomal formulations of an anticancer agent [mefenamic acid (MEF)] to enhance its cancer targeting. 131I was utilized as a radiolabeling isotope to study the radio-kinetics of MEF niosomes.

Methods

niosomal formulations were prepared by the ether injection method and assessed for entrapment efficiency (EE%), zeta potential (ZP), polydispersity index (PDI) and particle size (PS). MEF was labeled with 131I by direct electrophilic substitution reaction through optimization of radiolabeling-related parameters. In the radio-kinetic study, the optimal 131I-MEF niosomal formula was administered intravenously (I.V.) to solid tumor-bearing mice and compared to I.V. 131I-MEF solution as a control.

Results

the average PS and ZP values of the optimal formulation were 247.23 ± 2.32 nm and − 28.3 ± 1.21, respectively. The highest 131I-MEF labeling yield was 98.7 ± 0.8%. The biodistribution study revealed that the highest tumor uptake of 131I-MEF niosomal formula and 131I-MEF solution at 60 min post-injection were 2.73 and 1.94% ID/g, respectively.

Conclusion

MEF-loaded niosomes could be a hopeful candidate in cancer treatment due to their potent tumor uptake. Such high targeting was attributed to passive targeting of the nanosized niosomes and confirmed by radiokinetic evaluation.
Literature
Abbas Z, Rehman SJN (2018) An overview of cancer treatment modalities. Neoplasm 1:139–157
Aboud HM et al (2022) Tailoring of selenium-plated novasomes for fine-tuning pharmacokinetic and tumor uptake of quercetin: in vitro optimization and in vivo radiobiodistribution assessment in ehrlich tumor-bearing mice. Pharmaceutics 14(4):875 PubMedPubMedCentralCrossRef
Aboumanei MH, Mahmoud AF (2022) Development of tamoxifen in situ gel nanoemulsion for ocular delivery in photoreceptor degeneration disorder: in vitro characterization, 131I-Radiolabeling, and in vivo biodistribution studies. J Pharm Innov 18:369–380 CrossRef
Abou-Taleb HA, Khallaf RA, Abdel-Aleem JA (2018) Intranasal niosomes of nefopam with improved bioavailability: preparation, optimization, and in-vivo evaluation. Drug Des Dev Ther 12:3501–3516 CrossRef
Ahmed AM et al (2013) The application of Plackett-Burman design and response surface methodology for optimization of formulation variables to produce Piroxicam niosomes. Int J Drug Dev Res 5(2):121–130
Akbarzadeh I et al (2021) Niosomes: a novel targeted drug delivery system. Preprints, p 2021120315
Allam A et al (2021) Betaxolol-loaded niosomes integrated within pH-sensitive in situ forming gel for management of glaucoma. Int J Pharm 598:120380 PubMedCrossRef
Altay A et al (2019) Novel silver(I) complexes bearing mefenamic acid and pyridine derivatives: synthesis, chemical characterization and in vitro anticancer evaluation. Inorg Chim Acta 493:61–71 CrossRef
Amoabediny G et al (2018) Overview of preparation methods of polymeric and lipid-based (niosome, solid lipid, liposome) nanoparticles: a comprehensive review. Int J Polym Mater Polym Biomater 67(6):383–400 CrossRef
Anand U et al (2022) Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis 10(4):1367–1401 PubMedPubMedCentralCrossRef
Asaithambi K et al (2020) Synthesis and characterization of turAmoabedinymeric oil loaded non-ionic surfactant vesicles (niosomes) and its enhanced larvicidal activity against mosquito vectors. Biocatal Agric Biotechnol 29:101737 CrossRef
Atzrodt J, Derdau V, Loewe C (2020) Synthesis of radiolabelled compounds for clinical studies. In: Drug discovery and Evaluation: methods in clinical Ppharmacology, pp 807–825
Auda SH et al (2016) Niosomes as transdermal drug delivery system for celecoxib: in vitro and in vivo studies. Polym Bull 73(5):1229–1245 CrossRef
Avcıbaşı U et al (2013) Synthesis and biodistribution of novel magnetic-poly (HEMA–APH) nanopolymer radiolabeled with iodine-131 and investigation its fate in vivo for cancer therapy. J Nanopart Res 15:1–24 CrossRef
Aziz DE, Abdelbary AA, Elassasy AI (2018) Implementing central composite design for developing transdermal diacerein-loaded niosomes: ex vivo permeation and in vivo deposition. Curr Drug Deliv 15(9):1330–1342 PubMedPubMedCentralCrossRef
Bayrak E et al (2010) In vitro evaluation, biodistribution in rats of radiolabeled raloxifene. Appl Radiat Isot 68(1):33–36 PubMedCrossRef
Bernardi A et al (2008) Selective cytotoxicity of indomethacin and indomethacin ethyl ester-loaded nanocapsules against glioma cell lines: an in vitro study. Eur J Pharmacol 586(1–3):24–34 PubMedCrossRef
Bhardwaj P et al (2020) Niosomes: a review on niosomal research in the last decade. J Drug Deliv Sci Technol 56:101581 CrossRef
Bhardwaj G, Singh L, Sharma V (2015) Development of taste masked oral suspension of mefenamic acid and paracetamol for increase acceptability. Res J Pharm Biol Chem Sci 6(6)
Blevins HM et al (2022) The NLRP3 inflammasome pathway: a review of mechanisms and inhibitors for the treatment of inflammatory diseases. Front Aging Neurosci 14:879021 PubMedPubMedCentralCrossRef
Boseila AA et al (2019) Superiority of DEAE-Dx-stabilized cationic bile-based vesicles over conventional vesicles for enhanced hepatic delivery of daclatasvir. Mol Pharm 16(10):4190–4199 PubMedCrossRef
Chaudhari PD, Desai US (2019) Formulation and evaluation of niosomal in situ gel of prednisolone sodium phosphate for ocular drug delivery. Int J Appl Pharm 11:97–116 CrossRef
de Siqueira LBDO et al (2022) Encapsulation of photosensitizer in niosomes for promotion of antitumor and antimicrobial photodynamic therapy. J Drug Deliv Sci Technol. 68:103031 CrossRef
Edis Z et al (2021) Nanocarriers-mediated drug delivery systems for anticancer agents: an overview and perspectives. Int J Nanomed 16:1313 CrossRef
Eldin SSE et al (2023) Multifunctional 99mTc-5-azacitidine gold nanoparticles: formulation, in vitro cytotoxicity, radiosynthesis, and in vivo pharmacokinetic study. Curr Drug Deliv 20:387–399 PubMedCrossRef
El-Safoury D et al (2021) Amelioration of tumor targeting and in vivo biodistribution of 99mTc-methotrexate-gold nanoparticles (99mTc-Mex-AuNPs). J Pharm Sci 110(8):2955–2965 PubMedCrossRef
El-Sharawy DM et al (2022) Radiolabeling, biological distribution, docking and ADME studies of 99mTc-Ros as a promising natural tumor tracer. Appl Radiat Isot 184:110196 PubMedCrossRef
Faheela M, Malathi S (2022) In-vitro characterization of pluronic P 123 based niosome for targeted delivery of doxorubicin. Mater Today Proc 58:795–801 CrossRef
Fayed ND et al (2021) Chitosan-encapsulated niosomes for enhanced oral delivery of atorvastatin. J Drug Deliv Sci Technol 66:102866 CrossRef
Ghafelehbashi R et al (2019) Preparation, physicochemical properties, in vitro evaluation and release behavior of cephalexin-loaded niosomes. Int J Pharm 569:118580 PubMedCrossRef
Ghanem HA et al (2021) Comprehensive study of atorvastatin nanostructured lipid carriers through multivariate conceptualization and optimization. Pharmaceutics 13(2):178 PubMedPubMedCentralCrossRef
Guzman-Esquivel J et al (2020) Decreased biochemical progression in patients with castration-resistant prostate cancer using a novel mefenamic acid anti-inflammatory therapy: a randomized controlled trial. Oncol Lett 19(6):4151–4160 PubMedPubMedCentral
Guzman-Esquivel J et al (2022) Efficacy of the use of mefenamic acid combined with standard medical care vs. standard medical care alone for the treatment of COVID-19: a randomized double-blind placebo-controlled trial. Int J Mol Med 49(3):1–9 CrossRef
Haroun M et al (2022) Significant of injectable brucine PEGylated niosomes in treatment of MDA cancer cells. J Drug Deliv Sci Technol 71:103322 CrossRef
Hassan TH et al (2021) Refinement of Simvastatin and Nifedipine combined delivery through multivariate conceptualization and optimization of the nanostructured lipid carriers. J Drug Deliv Sci Technol 64:102570 CrossRef
He J et al (2019) Tumor targeting strategies of smart fluorescent nanoparticles and their applications in cancer diagnosis and treatment. Adv Mater 31(40):1902409 CrossRef
Hosseinimehr SJ et al (2015) Radioprotective effect of mefenamic acid against radiation-induced genotoxicity in human lymphocytes. Radiat Oncol J 33(3):256 PubMedPubMedCentralCrossRef
Hosseinimehr SJ et al (2019) The synergistic effect of mefenamic acid with ionizing radiation in colon cancer. J Bioenerg Biomembr 51(3):249–257 PubMedCrossRef
Hua S et al (2015) Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue. Nanomed Nanotechnol Biol Med 11(5):1117–1132 CrossRef
Jafarieh O et al (2015) Design, characterization, and evaluation of intranasal delivery of ropinirole-loaded mucoadhesive nanoparticles for brain targeting. Drug Dev Ind Pharm 41(10):1674–1681 PubMedCrossRef
Jimenez C, Erwin W, Chasen B (2019) Targeted radionuclide therapy for patients with metastatic pheochromocytoma and paraganglioma: from low-specific-activity to high-specific-activity iodine-131 metaiodobenzylguanidine. Cancers 11(7):1018 PubMedPubMedCentralCrossRef
Khan MI, Madni A, Peltonen L (2016) Development and in-vitro characterization of sorbitan monolaurate and poloxamer 184 based niosomes for oral delivery of diacerein. Eur J Pharm Sci 95:88–95 PubMedCrossRef
Khedr MA et al (2019) Rational design of some substituted phenyl azanediyl (bis) methylene phosphonic acid derivatives as potential anticancer agents and imaging probes: Computational inputs, chemical synthesis, radiolabeling, biodistribution and gamma scintigraphy. Bioorg Chem 92:103282 PubMedCrossRef
Kulkarni P, Rawtani D, Barot T (2021) Design, development and in-vitro/in-vivo evaluation of intranasally delivered Rivastigmine and N-Acetyl cysteine loaded bifunctional niosomes for applications in combinative treatment of Alzheimer’s disease. Eur J Pharm Biopharm 163:1–15 PubMedCrossRef
Kumar S et al (2022) Therapeutics effect of mesenchymal stromal cells in reactive oxygen species-induced damages. Hum Cell 35(1):37–50 PubMedCrossRef
Lohumi A (2012) A novel drug delivery system: niosomes review. J Drug Deliv Ther 2(5):129–135
Manohar M, Marzinke MA (2016) Application of chromatography combined with mass spectrometry in therapeutic drug monitoring. Clinical challenges in therapeutic drug monitoring. Elsevier, pp 45–70 CrossRef
Masjedi M, Montahaei T (2021) An illustrated review on nonionic surfactant vesicles (niosomes) as an approach in modern drug delivery: fabrication, characterization, pharmaceutical, and cosmetic applications. J Drug Deliv Sci Technol 61:102234 CrossRef
Moghddam SRM et al (2016) Formulation and optimization of niosomes for topical diacerein delivery using 3-factor, 3-level Box-Behnken design for the management of psoriasis. Mater Sci Eng C 69:789–797 CrossRef
Mousa IA et al (2022) Formulation and characterization of metformin-loaded ethosomes for topical application to experimentally induced skin cancer in mice. Pharmaceuticals 15(6):657 PubMedPubMedCentralCrossRef
Nasr T et al (2018) Novel hydrazide-hydrazone and amide substituted coumarin derivatives: synthesis, cytotoxicity screening, microarray, radiolabeling and in vivo pharmacokinetic studies. Eur J Med Chem 151:723–739 PubMedCrossRef
Navya P et al (2019) Current trends and challenges in cancer management and therapy using designer nanomaterials. Nano Converg 6:1–30 CrossRef
Nishu SBN et al (2018) In vitro and ex vivo studies of linagliptin loaded non-ionic surfactant vesicles using statistical optimization. J Adv Med Pharm Sci 18(2):1–16
Parveen S, Misra R, Sahoo SK (2012) Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomed Nanotechnol Biol Med 8(2):147–166 CrossRef
Puspaningtyas AR (2017) Drug development of mefenamic acid derivatives as analgesic by molecular approach. Int J Pharm Clin Res 9(2):123–130
Ramakrishnan R et al (1990) Nonuniform radiolabeling of VLDL apolipoprotein B: implications for the analysis of studies of the kinetics of the metabolism of lipoproteins containing apolipoprotein B. J Lipid Res 31(6):1031–1042 PubMedCrossRef
Rashed H et al (2014) Preparation of radioiodinated ritodrine as a potential agent for lung imaging. J Radioanal Nucl Chem 300(3):1227–1233 CrossRef
Rashed HM, Shamma RN, Basalious EB (2017a) Contribution of both olfactory and systemic pathways for brain targeting of nimodipine-loaded lipo-pluronics micelles: in vitro characterization and in vivo biodistribution study after intranasal and intravenous delivery. Drug Delivery 24(1):181–187 PubMedCentralCrossRef
Rashed H, Ibrahim I, Motaleb M (2017b) 99m Tc-hexoprenaline and 131 I-dapoxetine: preparation, in silico modeling and biological evaluation as promising lung scintigraphy radiopharmaceuticals. J Radioanal Nucl Chem 314:1297–1307 CrossRef
Rashed HM, Shamma RN, El-Sabagh HA (2018) Preparation of 99mTc-levetiracetam intranasal microemulsion as the first radiotracer for SPECT imaging of the synaptic vesicle protein SV2A. Eur J Pharm Sci 121:29–33 PubMedCrossRef
Saha GB, Saha GB (2004) Fundamentals of nuclear pharmacy, vol 6. Springer
Sakr TM et al (2017) Preparation and biological profile of 99m Tc-lidocaine as a cardioselective imaging agent using 99m Tc eluted from 99 Mo/99m Tc generator based on Al–Mo gel. J Radioanal Nucl Chem 314:2091–2098 CrossRef
Sayyad N et al (2021) Development of niosomes for encapsulating captopril-quercetin prodrug to combat hypertension. Int J Pharm 609:121191 PubMedCrossRef
Seger C (2012) Usage and limitations of liquid chromatography-tandem mass spectrometry (LC–MS/MS) in clinical routine laboratories. Wien Med Wochenschr 162(21):499–504 PubMedCrossRef
Seyyedi R et al (2022) Mefenamic acid as a promising therapeutic medicine against colon cancer in tumor-bearing mice. Med Oncol 39(2):18 PubMedCrossRef
Sharma S, Bhatt S, Saini V (2021) Formulation development and evaluation of novel vesicular carrier for enhancement of bioavailability of poorly soluble drug. Pharm Nanotechnol 9(1):70–82 PubMedCrossRef
Shewaiter MA et al (2021) Formulation and characterization of leflunomide/diclofenac sodium microemulsion base-gel for the transdermal treatment of inflammatory joint diseases. J Drug Deliv Sci Technol 61:102110 CrossRef
Shilakari Asthana G, Sharma PK, Asthana A (2016) In vitro and in vivo evaluation of niosomal formulation for controlled delivery of clarithromycin. Scientifica 2016:6492953 PubMedPubMedCentralCrossRef
Soriano-Hernández AD et al (2012) Antitumor effect of meclofenamic acid on human androgen-independent prostate cancer: a preclinical evaluation. Int Urol Nephrol 44:471–477 PubMedCrossRef
Soriano-Hernandez AD et al (2015) Anti-inflammatory drugs and uterine cervical cancer cells: Antineoplastic effect of meclofenamic acid. Oncol Lett 10(4):2574–2578 PubMedPubMedCentralCrossRef
Targhi AA et al (2021) Synergistic effect of curcumin-Cu and curcumin-Ag nanoparticle loaded niosome: enhanced antibacterial and anti-biofilm activities. Bioorg Chem 115:105116 PubMedCrossRef
Temprom L et al (2022) A novel preparation and characterization of melatonin loaded niosomes based on using a ball milling method. Mater Today Commun 31:103340 CrossRef
Thabet Y, Elsabahy M, Eissa NG (2022) Methods for preparation of niosomes: a focus on thin-film hydration method. Methods 199:9–15 PubMedCrossRef
Utami D, Nugrahani I, Ibrahim S (2017) Mefenamic acid-nicotinamide co-crystal synthesized by using melt crystallization method and its solubility study. Asian J Pharm Clin Res 10:135–139 CrossRef
Vogel HG, Maas J, Mayer D (2006) Drug discovery and evaluation: safety and pharmacokinetic assays; with 125 tables. Springer Science & Business Media CrossRef
Wichianphong N, Charoenchaitrakool M (2018) Statistical optimization for production of mefenamic acid–nicotinamide cocrystals using gas anti-solvent (GAS) process. J Ind Eng Chem 62:375–382 CrossRef
Witika BA, Walker RB (2021) Preformulation characterization and identification of excipients for nevirapine loaded niosomes. Die Pharmazie-an Int J Pharm Sci 76(2–3):77–83
Wong RS (2019) Role of nonsteroidal anti-inflammatory drugs (NSAIDs) in cancer prevention and cancer promotion. Adv Pharm Sci 2019:3418975
Woo DH, Han I-S, Jung G (2004) Mefenamic acid-induced apoptosis in human liver cancer cell-lines through caspase-3 pathway. Life Sci 75(20):2439–2449 PubMedCrossRef
Xiao C et al (2021) Biomimetic nanoparticles loading with gamabutolin-indomethacin for chemo/photothermal therapy of cervical cancer and anti-inflammation. J Control Release 339:259–273 PubMedCrossRef
Yasamineh S et al (1878) A state-of-the-art review on the recent advances of niosomes as a targeted drug delivery system. Int J Pharm 2022:12
Zha S et al (2001) Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Can Res 61(24):8617–8623
Metadata
Title
Niosomal formulation of mefenamic acid for enhanced cancer targeting; preparation, characterization and biodistribution study using radiolabeling technique
Authors
Mona A. Shewaiter
Adli A. Selim
Hassan M. Rashed
Yasser M. Moustafa
Shadeed Gad
Publication date
20-11-2023
Publisher
Springer Berlin Heidelberg
Published in
Journal of Cancer Research and Clinical Oncology
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-023-05482-8
Webinar | 08-11-2023 | 18:00 (CET)

Keynote Webinar | Spotlight on Diet and Diabetes

Watch now

An expert-led symposium exploring the prevention and management of type 2 diabetes through dietary interventions. Highlights include discussion of the recent EASD guidelines, therapeutic diets, food types and processing, plus psychological factors that influence patient success, and the drivers of healthy eating and diabetes control.
Prof. Mike Lean
Prof. Falko Sniehotta
Image Credits